Prostate specific antigen, the clinical marker for prostate cancer, is a neutral serine protease whose function is to lyse seminal proteins. Recent work by our laboratory has suggested that prostate specific antigen stimulates the generation of reactive oxygen species in prostate cancer cells. Using 2',7'-dichlorofluorescin diacetate, a dye that fluoresces in the presence of hydrogen peroxide o...

Lymph node (LN) metastasis is considered an important prognostic factor in patients with prostate cancer. The aim of this study was to determine the rate of LN metastasis among an Iranian population who underwent radical prostatectomy (RP) with pelvic LN dissection (PLND). In a retrospective review of medical records, 450 RP cases were included and the data on LN metastasis were extracted from ...

Background: Prostate specific antigen (PSA) has been used as a screening test for the early detection of prostate cancer (PC) for many years. Although the introduction of PSA test led to a considerable increase in reported prostate cancer cases, there is still some controversy over the sensitivity and specificity of this marker in distinguishing PC patients from those with benign prostate hyper...

Background: Immunoradiometric assay is one of the most common and precise methods for determination of prostate specific antigen (PSA) in clinical laboratories. Usual use of human serum in routine assays has many disadvantages such as easy contamination and precipitation, instability and unavailability. Thus in order to avoid these problems the artificial matrix was used which acts sim...

Introduction Transient decrease in serum prostate-specific antigen level can occur after abiraterone acetate withdrawal male patient with metastatic castration-resistant prostate cancer. Here, we report a case of syndrome transient progression to disease while using upfront therapy for high-risk Case presentation A 73-year-old man hormone-sensitive cancer multiple bone metastases (prostate-spec...

Introduction: Medical malpractice and prostate cancer screening are important issues in the current landscape of health care. We identified factors contributing to litigation in the diagnosis of prostate cancer. Methods: We used the Westlaw database to search for jury verdict reports using the term medical malpractice combined with prostate cancer with dates ranging from January 2000 to Decembe...

According to available estimates with WHO, cancers are the sixth leading cause of global human morbidity and mortality. Prostate Cancer is fifth-ranked most lethal among various cancers, hence it warrants serious, dedicated research for improving its early detection. The employed methodologies such as prostate-specific antigen test, Gleason Score, T2 Staging lack precision accuracy in condition...

Background and Objective: Adenocarcinoma of the prostate is the second most common cause of cancer. The loss of CD10 is a common early event in human prostate cancer and is seen in lower Gleason Score malignancies while increased and altered expression is seen in high Gleason Score tumors, lymph nodes and bone metastasis. Material and Methods: This was a ...

Abstract The PSA test is used primarily to screen for prostate cancer. A measures the amount of prostate-specific antigen (PSA) in your blood. a protein produced prostate, small gland that sits below man's bladder. mostly found semen, which also prostate. Small amounts ordinarily circulate can detect high levels may indicate presence However, many other conditions, such as an enlarged or inflam...

Background: Oxidants and inflammation agents are predisposing factors for the development of prostate cancer. As a chemical warfare, sulfur mustard (SM) can cause cancer through various pathways mainly increased production of oxidants and inflammation. Due to high incidence of cancer in SM victims, concentration of prostate specific antigen (PSA) in SM victims was evaluated and compared with th...